BACKGROUND: This study was designed to better define the role of radiation (Neo-Rad) in addition to neoadjuvant multiagent chemotherapy (NAT) for the treatment of locally advanced pancreatic cancer. METHODS: Retrospective cohort study using the NCDB. Individuals with AJCC clinical T3/T4 pancreatic carcinoma who underwent resection and multiagent chemotherapy were included. Kaplan-Meier, logistic-regression, and Cox proportional-hazard models were used for analysis. RESULTS: A total of 2703 patients were included; 2039 had T3 and 664 had T4 tumors, and 1092 (40.4%) received Neo-Rad. Median follow-up was 22.5 months. During the study period, there was increased use of NAT and a decline in the use of Neo-Rad. Addition of Neo-Rad did not affect...
Context For patients with borderline resectable pancreatic cancer, the benefit of neoadjuvant therap...
AbstractObjectivesThis study investigated the impact of neoadjuvant radiation therapy (XRT) on posto...
The overall survival of patients with resectable or borderline-resectable pancreatic ductal adenocar...
BACKGROUND: This study was designed to better define the role of radiation (Neo-Rad) in addition to ...
Objective: The aim of this study was to pool data from randomized controlled trials (RCT) limited to...
OBJECTIVE The aim of this study was to pool data from randomized controlled trials (RCT) limited ...
The prevalence of pancreatic cancer is sharply increasing recently, which significantly increases th...
none9noBackground: We compare neoadjuvant chemoradiation therapy plus surgery versus surgery alone i...
Background: The use of neoadjuvant chemotherapy (NAC) for pancreatic ductal adenocarcinoma (PDAC) ha...
<p><b>Background:</b> Neoadjuvant therapy for pancreatic cancer remains controversial. Our aim was t...
Abstract Background Few patients with pancreatic cancer may be candidates for immediate surgical res...
BACKGROUND AND PURPOSE: Neoadjuvant chemoradiation could improve survival in patients with pancreati...
BACKGROUND: The value of neoadjuvant radiotherapy (RT) after 5-fluorouracil with leucovorin, oxalipl...
OBJECTIVE: This study was performed to determine whether neoadjuvant treatment increases survival in...
BACKGROUND: Downstaging has been associated with improved survival for many cancers. However, the im...
Context For patients with borderline resectable pancreatic cancer, the benefit of neoadjuvant therap...
AbstractObjectivesThis study investigated the impact of neoadjuvant radiation therapy (XRT) on posto...
The overall survival of patients with resectable or borderline-resectable pancreatic ductal adenocar...
BACKGROUND: This study was designed to better define the role of radiation (Neo-Rad) in addition to ...
Objective: The aim of this study was to pool data from randomized controlled trials (RCT) limited to...
OBJECTIVE The aim of this study was to pool data from randomized controlled trials (RCT) limited ...
The prevalence of pancreatic cancer is sharply increasing recently, which significantly increases th...
none9noBackground: We compare neoadjuvant chemoradiation therapy plus surgery versus surgery alone i...
Background: The use of neoadjuvant chemotherapy (NAC) for pancreatic ductal adenocarcinoma (PDAC) ha...
<p><b>Background:</b> Neoadjuvant therapy for pancreatic cancer remains controversial. Our aim was t...
Abstract Background Few patients with pancreatic cancer may be candidates for immediate surgical res...
BACKGROUND AND PURPOSE: Neoadjuvant chemoradiation could improve survival in patients with pancreati...
BACKGROUND: The value of neoadjuvant radiotherapy (RT) after 5-fluorouracil with leucovorin, oxalipl...
OBJECTIVE: This study was performed to determine whether neoadjuvant treatment increases survival in...
BACKGROUND: Downstaging has been associated with improved survival for many cancers. However, the im...
Context For patients with borderline resectable pancreatic cancer, the benefit of neoadjuvant therap...
AbstractObjectivesThis study investigated the impact of neoadjuvant radiation therapy (XRT) on posto...
The overall survival of patients with resectable or borderline-resectable pancreatic ductal adenocar...